Figg WD - Search Results

1

Paclitaxel (taxol) inhibits protein isoprenylation and induces apoptosis in PC-3 human prostate cancer cells.

Danesi R, Figg WD, Reed E, Myers CE. Danesi R, et al. Among authors: figg wd. Mol Pharmacol. 1995 Jun;47(6):1106-11. Mol Pharmacol. 1995. PMID: 7603448

2

Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer.

Sartor O, Cooper M, Weinberger M, Headlee D, Thibault A, Tompkins A, Steinberg S, Figg WD, Linehan WM, Myers CE. Sartor O, et al. Among authors: figg wd. J Natl Cancer Inst. 1994 Feb 2;86(3):222-7. doi: 10.1093/jnci/86.3.222. J Natl Cancer Inst. 1994. PMID: 7506794

3

A phase I study of the somatostatin analogue somatuline in patients with metastatic hormone-refractory prostate cancer.

Figg WD, Thibault A, Cooper MR, Reid R, Headlee D, Dawson N, Kohler DR, Reed E, Sartor O. Figg WD, et al. Cancer. 1995 Apr 15;75(8):2159-64. doi: 10.1002/1097-0142(19950415)75:8<2159::aid-cncr2820750820>3.0.co;2-o. Cancer. 1995. PMID: 7535186 Clinical Trial.

4

Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer.

Figg WD, Sartor O, Cooper MR, Thibault A, Bergan RC, Dawson N, Reed E, Myers CE. Figg WD, et al. Am J Med. 1995 Apr;98(4):412-4. doi: 10.1016/S0002-9343(99)80323-4. Am J Med. 1995. PMID: 7535978 Clinical Trial. No abstract available.

5

A preliminary risk-benefit assessment of paclitaxel.

Bitton RJ, Figg WD, Reed E. Bitton RJ, et al. Among authors: figg wd. Drug Saf. 1995 Mar;12(3):196-208. doi: 10.2165/00002018-199512030-00005. Drug Saf. 1995. PMID: 7619331 Review.

6

Disposition of phenylbutyrate and its metabolites, phenylacetate and phenylacetylglutamine.

Piscitelli SC, Thibault A, Figg WD, Tompkins A, Headlee D, Lieberman R, Samid D, Myers CE. Piscitelli SC, et al. Among authors: figg wd. J Clin Pharmacol. 1995 Apr;35(4):368-73. doi: 10.1002/j.1552-4604.1995.tb04075.x. J Clin Pharmacol. 1995. PMID: 7650225 Clinical Trial.

7

Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin.

Bitton RJ, Figg WD, Venzon DJ, Dalakas MC, Bowden C, Headlee D, Reed E, Myers CE, Cooper MR. Bitton RJ, et al. Among authors: figg wd. J Clin Oncol. 1995 Sep;13(9):2223-9. doi: 10.1200/JCO.1995.13.9.2223. J Clin Oncol. 1995. PMID: 7666080 Clinical Trial.

8

Phase I study of phenylacetate administered twice daily to patients with cancer.

Thibault A, Samid D, Cooper MR, Figg WD, Tompkins AC, Patronas N, Headlee DJ, Kohler DR, Venzon DJ, Myers CE. Thibault A, et al. Among authors: figg wd. Cancer. 1995 Jun 15;75(12):2932-8. doi: 10.1002/1097-0142(19950615)75:12<2932::aid-cncr2820751221>3.0.co;2-p. Cancer. 1995. PMID: 7773944 Clinical Trial.

9

In vitro antitumor effect of hydroxyurea on hormone-refractory prostate cancer cells and its potentiation by phenylbutyrate.

Figg WD, Walls RG, Cooper MR, Thibault A, Sartor O, McCall NA, Myers CE, Samid D. Figg WD, et al. Anticancer Drugs. 1994 Jun;5(3):336-42. doi: 10.1097/00001813-199406000-00012. Anticancer Drugs. 1994. PMID: 7919459

10

Acute renal toxicity associated with suramin in the treatment of prostate cancer.

Figg WD, Cooper MR, Thibault A, Headlee D, Humphrey J, Bergan RC, Reed E, Sartor O. Figg WD, et al. Cancer. 1994 Sep 1;74(5):1612-4. doi: 10.1002/1097-0142(19940901)74:5<1612::aid-cncr2820740519>3.0.co;2-q. Cancer. 1994. PMID: 8062193

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

789 results

Search Page

Filters